Sunflower Bank NA Wealth Management Sells 4,675 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Sunflower Bank NA Wealth Management trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,104 shares of the biopharmaceutical company’s stock after selling 4,675 shares during the quarter. Pfizer accounts for approximately 0.6% of Sunflower Bank NA Wealth Management’s holdings, making the stock its 25th biggest holding. Sunflower Bank NA Wealth Management’s holdings in Pfizer were worth $1,839,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB grew its stake in Pfizer by 65.3% in the 2nd quarter. Nordea Investment Management AB now owns 22,272,402 shares of the biopharmaceutical company’s stock worth $719,176,000 after acquiring an additional 8,798,233 shares in the last quarter. Two Sigma Advisers LP grew its stake in Pfizer by 74.8% in the 2nd quarter. Two Sigma Advisers LP now owns 11,066,501 shares of the biopharmaceutical company’s stock worth $361,875,000 after acquiring an additional 4,736,500 shares in the last quarter. APG Asset Management N.V. grew its stake in Pfizer by 129.4% in the 1st quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock worth $227,038,000 after acquiring an additional 3,924,241 shares in the last quarter. BlackRock Inc. grew its stake in Pfizer by 0.8% in the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after acquiring an additional 3,464,207 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Pfizer by 8,940.8% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,426,457 shares of the biopharmaceutical company’s stock valued at $112,045,000 after purchasing an additional 3,388,557 shares in the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.

PFE traded up $0.75 during trading on Friday, hitting $38.18. The stock had a trading volume of 28,992,325 shares, compared to its average volume of 20,809,482. The stock has a 50 day simple moving average of $36.59 and a two-hundred day simple moving average of $36.49. The company has a market capitalization of $212.16 billion, a PE ratio of 15.15, a PEG ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company posted $0.80 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.84 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.98%. Pfizer’s dividend payout ratio is currently 51.53%.

In related news, Director Ronald E. Blaylock purchased 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.08% of the company’s stock.

A number of research firms have recently issued reports on PFE. Truist began coverage on shares of Pfizer in a research note on Friday. They set a “buy” rating and a $42.00 price objective on the stock. UBS Group increased their price objective on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Atlantic Securities downgraded shares of Pfizer from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Berenberg Bank began coverage on shares of Pfizer in a research note on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective on the stock. Finally, Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, October 16th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus price target of $39.81.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What is the Fibonacci sequence?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.